Distributor vs Commercial Agent vs Subsidiary in Germany (2026): Which Market‑entry Model Is Best for Pharma, Medtech & Digital‑health?

Every pharma, medtech or digital‑health company eyeing the German market faces the same threshold question: appoint a distributor, engage a commercial agent, or incorporate a German subsidiary (GmbH)? The choice between distributor vs commercial agent vs subsidiary in Germany in 2026 carries heavier consequences than it did even two years ago, because recent case‑law commentary and practitioner alerts have materially increased the indemnity and liability exposure that principals face when they rely on third‑party channels.

This article delivers a concrete, dimension‑by‑dimension decision framework, covering regulatory burden under the EU MDR and IVDR, AMNOG reimbursement strategy, tax implications, termination liability and enforceability, so that commercial directors and in‑house counsel can select the model that fits their product, their timeline and their risk appetite.

Option A: The Distributor Model

A distributor is an independent reseller. It purchases products from the manufacturer, takes title to stock and resells into the German market at its own commercial risk. The manufacturer’s control is limited to what the distribution agreement prescribes, exclusive territories, minimum purchase volumes, price recommendations (as distinct from binding resale‑price maintenance, which is prohibited under EU competition law) and reporting obligations.

For life‑sciences companies pursuing market entry in Germany for medtech products, the distributor route offers clear advantages:

• Speed. A distribution agreement can be executed in days. There is no corporate formation, no German payroll and no local management board to appoint.
• Local logistics and relationships. An established German distributor brings warehousing, existing hospital and clinic contacts, and, critically, familiarity with procurement processes and statutory health‑insurance billing.
• Limited overhead. The principal avoids German corporate taxes entirely, provided the arrangement does not create a permanent establishment (PE).

The disadvantages are significant, however, especially after 2026 developments in distributor indemnity litigation. Under German case law, courts have increasingly applied the commercial‑agent indemnity rules by analogy to distributors who are integrated into the manufacturer’s sales organisation. Early 2026 practitioner commentary confirmed that distributors may assert a post‑termination indemnity claim (Ausgleichsanspruch) even though this right is not directly codified for distributors in the German Commercial Code (HGB). The principal also surrenders pricing control and, under EU MDR 2017/745, must ensure clear allocation of importer and distributor obligations, an assignment that becomes complicated when the distributor performs activities (labelling, repackaging) that push it into the importer category.

A distributor model works best for an early‑stage launch of a non‑implantable, CE‑marked medtech product where a local partner already holds reimbursement relationships and the manufacturer accepts lower margin control in exchange for speed.

Option B: The Commercial Agent

A commercial agent (Handelsvertreter) is a self‑employed intermediary who negotiates or concludes sales on behalf of the principal, earning commission rather than a resale margin. German commercial‑agent law is codified in HGB §§ 84–92c and implements EU Directive 86/653/EEC. These provisions are largely mandatory, they cannot be contracted away to the agent’s disadvantage.

The distribution vs agency Germany distinction matters most on two fronts: control and exit cost.

• Control. Because the agent acts in the principal’s name, the principal sets the commercial terms, price, delivery, warranty scope. This is a significant advantage over the distributor model for manufacturers that need to protect list‑price integrity for reimbursement benchmarking.
• Exit cost. Under HGB § 89b, a commercial agent is entitled to a post‑termination indemnity if the agent has brought new customers or significantly increased the volume of business with existing customers and the principal continues to derive substantial benefits from that customer base. The indemnity is capped at one year’s average commission, but it cannot be waived in advance.

Early 2026 practitioner updates highlighted that disputes over one‑off commissions and the question of whether the agent loses ongoing commission income remain a perennial source of litigation. The likely practical effect of the latest commentary is that principals must budget for indemnity reserves from day one and ensure that commission structures are documented with enough granularity to withstand judicial review.

A commercial agent suits a manufacturer that wants local representation and customer introductions without holding inventory, and that can accept the statutory protections, including mandatory minimum notice periods under HGB § 89, as part of the cost of doing business.

Option C: The German Subsidiary (GmbH)

Incorporating a Gesellschaft mit beschränkter Haftung (GmbH) creates a separate German legal entity with its own management, tax obligations and liability perimeter. Formation requires a minimum share capital of €25,000 under the GmbHG, of which at least €12,500 must be paid in at registration. Notarisation, commercial‑register filing and initial accounting setup typically take four to eight weeks.

For pharma, medtech and digital‑health firms, a subsidiary vs distributor Germany analysis increasingly favours the GmbH once any of the following conditions are met:

• Full reimbursement control. If the product is subject to AMNOG benefit assessment (pharmaceuticals) or requires direct negotiation with the G‑BA or statutory health‑insurance funds, a local entity provides the standing and the operational infrastructure to manage the dossier, the pricing negotiation and the ongoing evidence generation.
• MDR/IVDR role clarity. Under EU MDR 2017/745 (Articles 13–16), the obligations of manufacturer, authorised representative, importer and distributor are distinct. A GmbH can serve as the authorised representative or as the importer, giving the parent company clear regulatory accountability without relying on a third party whose contractual compliance is harder to enforce.
• High‑liability products. For implantable devices, Class III medical devices or combination products, the corporate veil of a GmbH contains product‑liability exposure within the German entity, a meaningful risk‑management benefit.
• Long‑term market commitment. Where projected German revenue justifies the ongoing compliance cost (payroll, statutory audit, trade‑tax filing), the GmbH eliminates margin leakage to intermediaries and reduces the indemnity risks that accompany both agent and distributor terminations.

The GmbH is subject to corporate income tax at 15 % plus a solidarity surcharge of 5.5 % on the corporate‑tax amount, and to municipal trade tax (Gewerbesteuer) at rates that vary by municipality. The combined effective tax rate typically falls in the range of 30–33 %. VAT registration is mandatory; the standard rate is 19 %.

Distributor vs Commercial Agent vs Subsidiary: Side‑by‑Side Comparison

Choose a Distributor when you need the fastest commercial access with minimal local overhead and can accept lower pricing control plus rising contractual risk.

Choose a Commercial Agent when you want local representation with limited capital commitment and can accommodate HGB agent protections including potential termination compensation.

Choose a German Subsidiary (GmbH) when you require full control of reimbursement and MDR responsibilities, face high product liability, or expect sustained German revenue that justifies incorporation.

Dimension‑by‑Dimension Analysis: Distributor vs Commercial Agent vs Subsidiary in Germany

Tax implications

Tax treatment is one of the clearest differentiators between a subsidiary vs distributor in Germany. The following table summarises the key fiscal exposures.

Cost and pricing impact

A distributor typically adds a margin of 20–40 % on top of the manufacturer’s transfer price. Over a three‑to‑five‑year horizon, the cumulative margin leakage can exceed the full cost of forming and operating a GmbH, particularly once German revenues surpass approximately €2–3 million per year. Manufacturers should model the break‑even point before committing to an exclusive, long‑term distribution agreement.

Liability and indemnity, the 2026 shift

Liability and indemnity in Germany in 2026 represent the single most changed dimension for this decision. Two developments demand attention:

• Distributor indemnity claims. Courts continue to apply the agent‑indemnity provisions of HGB § 89b by analogy to distributors who are closely integrated into the manufacturer’s distribution system. Early 2026 commentary confirmed that this indemnity claim is not directly regulated by statute for distributors, but manufacturers cannot safely assume it will not arise.
• Agent commission disputes. Whether a commercial agent is entitled only to one‑off commissions, and therefore loses no ongoing commission income on termination, remains a recurring litigation issue. Industry observers expect courts to scrutinise commission structures closely, with the practical effect that principals should assume worst‑case indemnity exposure unless the commission agreement is drafted with forensic precision.

Regulatory burden under MDR and IVDR

Under EU MDR 2017/745 (Articles 13–16) and EU IVDR 2017/746, the obligations of manufacturer, authorised representative, importer and distributor are distinct and non‑delegable. A distributor that relabels, repackages or alters the device may assume importer or even manufacturer obligations, exposing both the distributor and the principal to regulatory enforcement. A GmbH can be assigned a specific regulatory role (authorised representative, importer or local manufacturer) with full documentary control, eliminating the ambiguity that third‑party channels introduce.

Reimbursement and market access

For pharmaceuticals subject to AMNOG benefit assessment, the manufacturer must submit a dossier to the G‑BA and negotiate a reimbursement price with the GKV‑Spitzenverband. This process typically runs 12–18 months from launch. A distributor can handle logistics, but the reimbursement dossier, the pricing negotiation and the post‑launch evidence generation require a level of strategic control that only a local entity, or a very tightly contracted agent, can deliver. For a deeper analysis of Germany drug pricing and reimbursement in 2026, see our dedicated guide.

Timing and speed to market

A distribution or agency agreement can be concluded in days. GmbH formation requires four to eight weeks (notarisation, commercial‑register entry, tax registration, bank‑account opening). For time‑critical launches, such as a medtech pilot with a fixed hospital‑procurement window, starting with a distributor or agent and migrating to a GmbH once revenue justifies it is a legitimate staged strategy.

What Changes in 2026

Two practitioner alerts published in early 2026 crystallise the shifting risk landscape for principals using third‑party channels in Germany:

• Commercial agency update (February 2026). The alert highlighted that the question of whether a commercial agent is entitled only to one‑off commissions, and therefore loses no ongoing commission income on termination, remains unresolved and heavily litigated. Principals should treat agent‑indemnity reserves as a mandatory line item in their German market‑entry budget.
• Distributor indemnity commentary (January 2026). Practitioners confirmed that distributors may assert a post‑termination indemnity claim by analogy to HGB § 89b. This claim is not directly regulated by statute, but contractual carve‑outs face increasing judicial scrutiny. The practical effect: termination of a long‑standing distributor relationship now carries indemnity exposure that many principals have not priced into their agreements.

The combined impact of these developments is that the traditional cost advantage of third‑party distribution, lower overhead, no German corporate presence, is eroded by higher exit costs and litigation risk. For high‑value life‑sciences products, this often tips the balance toward earlier GmbH formation.

Decision Framework: When to Choose Distributor, Agent or GmbH

Start with three questions: (1) Does your product carry high regulatory or product‑liability risk? (2) Does your reimbursement strategy require direct payer negotiation under AMNOG or G‑BA processes? (3) Do you expect German revenue to exceed €2–3 million within 24 months?

If the answer to any of these is yes, the subsidiary vs distributor Germany analysis points firmly toward a GmbH. If none apply, a distributor or agent provides a lower‑cost entry point, with the option to incorporate later.

Choose Distributor when:

• You need immediate stock presence in German hospitals or clinics.
• The product has straightforward reimbursement and low regulatory complexity.
• You can accept less direct control over pricing and customer relationships.

Choose Commercial Agent when:

• You want local representation and customer introductions without inventory risk.
• You accept statutory agent protections under HGB §§ 84–92c and the commission structure they require.
• You need to maintain list‑price integrity for reimbursement benchmarking.

Choose GmbH when:

• You need to lead AMNOG benefit assessment or direct G‑BA negotiations.
• You must serve as importer or authorised representative under MDR/IVDR.
• You sell high‑liability products (implants, Class III devices, combination products).
• You plan sustained direct sales and expect German revenue to justify incorporation costs.

Example scenarios

• Early‑stage medtech SaaS pilot. A CE‑marked software‑as‑a‑medical‑device running a six‑month pilot with two German hospital networks. Revenue: under €500k. Recommendation: commercial agent for introductions; defer GmbH until scaling.
• Implantable orthopaedic device launch. Class III device, full AMNOG dossier required, projected year‑two revenue €5 million. Recommendation: GmbH from day one, the liability, reimbursement and regulatory demands outweigh the setup cost.
• Digital‑health app seeking DiGA listing. The DiGA fast‑track pathway requires a German entity or authorised representative to interact with BfArM. Recommendation: GmbH or, as a staged approach, authorised‑representative arrangement with a clear migration plan to GmbH once listing is achieved.

When to Engage a Lawyer

Certain trigger points in the distributor vs commercial agent vs subsidiary Germany 2026 decision move the analysis beyond internal planning and into territory where specialist counsel is essential:

• Drafting termination and indemnity clauses in agent or distributor agreements, particularly given the 2026 increase in judicial scrutiny of contractual carve‑outs.
• Appointing a commercial agent where HGB §§ 84–92c mandatory protections apply and commission structures must withstand litigation.
• Structuring transfer pricing and trade‑tax exposure for a newly formed GmbH, including intercompany supply agreements and PE‑risk analysis.
• Assigning MDR/IVDR regulatory roles, manufacturer, authorised representative, importer, to ensure each party’s obligations are contractually documented and enforceable.
• Building AMNOG dossier and pricing strategy that requires coordination between regulatory, reimbursement and commercial counsel.

The most effective approach is to engage a cross‑discipline adviser who covers regulatory, reimbursement, commercial contracting and tax in a single engagement, avoiding the fragmentation that drives up cost and delay. To find a Germany life‑sciences lawyer, consult the Global Law Experts directory or request a scoping call.

Sources

1. German Commercial Code (HGB), Sections 84–92c
2. EU Medical Device Regulation (MDR, 2017/745)
3. EU In Vitro Diagnostic Regulation (IVDR, 2017/746)
4. G‑BA (Gemeinsamer Bundesausschuss), AMNOG Guidance
5. Noerr, Commercial Update 2026: Commercial Agency Agreements
6. Advant Beiten, The Distributor’s Indemnity Claim Under German Law
7. Bundesministerium der Finanzen (BMF)
8. Taylor Wessing, Distribution & Agency in Germany
9. Handelsvertreter.de, CDH (German Commercial Agents Trade Body)